Epidarex Capital
Overview
Epidarex Capital is a transatlantic venture firm that invests in early-stage, high-growth life science companies in under-ventured markets. Epidarex focuses on providing risk capital and expertise to create, support and build young companies, including spinouts, from leading research institutions in both established and emerging life science hubs. The fund's international management team has a track record of successfully partnering with top scientists and entrepreneurs to develop highly innovative products for the global healthcare market.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| RapidPulse | Jul 2026 | Series B | Co-investor |
| NodThera | Apr 2025 | Series D | Co-investor |
| Leucid Bio | Feb 2025 | Series A Extension | Lead |
| Harness Therapeutics | Jan 2025 | VC Round | Co-investor |
| Epsilogen | Sep 2024 | Series B Extension | Lead |
Key People
Kyparissia Sirinakis
Co-Founder Managing Partner
Sinclair Dunlop
Managing Partner
Henning Steinhagen
Venture Partner
Lori Gough
Partner
Peter Finan
Partner
Matthew Miessau
Principal
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
